MedTrace Logo

Psoriatic Arthritis Study of Izokibep

NCT05623345 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 351

Last updated 2025-05-23

Study results available
· View outcomes & findings →

Summary

Izokibep is a potent and selective inhibitor of interleukin (IL)-17A that is being developed for treatment of psoriatic arthritis (PsA).

This study will evaluate the efficacy of izokibep in subjects with PsA.

Conditions

Interventions

DRUG

Izokibep

Biologic: IL-17A inhibitor Form: Solution for injection Route of administration: Subcutaneous (SC)

DRUG

Placebo to izokibep

Form: Solution for injection Route of administration: Subcutaneous (SC)

Sponsors & Collaborators

  • ACELYRIN Inc.

    lead INDUSTRY

Principal Investigators

  • Shepard Mpofu, MD, Clinical Development · ACELYRIN Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-21
Primary Completion
2023-11-30
Completion
2024-08-08
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Canada
  • Czechia
  • Germany
  • Hungary
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05623345 on ClinicalTrials.gov